Founded on 19 July 1994, Claris Lifesciences Limited is a Public Limited Company it is involved in Human Healthcare Activities. It is registered at the registrar of companies in Ahmedabad. The authorized equity capital of the company is Rs. 1,205,100,030 and the paid-up capital is Rs. 545,677,630.
Shares of Claris Lifesciences Limited were listed on the BSE. The company's shares stopped trading on BSE on March 15, 2018, and it was delisted from the BSE on March 22, 2018. The exit offer price was Rs. 400 per share for public shareholders.
Claris Life Sciences Outstanding Shares: |
54,567,765 |
Face Value of Claris Life Science Unlisted Share: |
Rs. 10 Per Equity Shares |
ISIN of Claris Life Sciences Limited Unlisted Share: |
INE562G01018 |
Lot Size of Claris Life Sciences Unlisted Share: |
100 Shares |
Claris Life Sciences Limited Share Price: |
Best in Industry |
PAN Number of Claris Life Sciences: |
AAACC6366Q |
Claris Life Sciences CIN Number |
U85110GJ1994PLC022543 |
Claris Life Sciences Registration Date |
19-Jul-94 |
Category / Sub-Category of Claris Life Sciences |
Company limited by Shares |
Claris Life Sciences Limited Registered Office Address |
Coporate Towers" Nr. Parimal, Crossing, Ellisbridge, Ahemdabad - 380006 |
Claris Life Sciences Limited Registrar & Transfer Agent Address and Contact Details |
Link InTime India Private Limited C 101, 247 Park, 1st Floor L.B.S. Marg, Vikhroli West, Mumbai - 400083, Tel. No.: 022 - 49186270 |
|
S. No. |
Name of the Company |
Subsidiary |
% of shares held |
|
Foreign Subsidiaries |
|||
|
1. |
Claris Life Sciences Venezuela C.A. |
Subsidiary |
100% |
|
2. |
PT. Claris Life Sciences Indonesia |
Subsidiary |
100% |
Mr. Surrinder Lal Kapur (Chairman & Non-Executive and Independent Director)
Mr. Arjun Handa (Vice-Chairman & Managing Director)
Mr. Aditya S. Handa (Non-Executive and Non-Independent Director)
Mr. Chandrasingh S. Purohit (Whole Time Director & CFO)
Mr. Shyamsunder Sharma (Non-Executive and Non-Independent Director)
Dr. Anup P. Shah (Non-Executive and Independent Director)
|
S. No. |
Shareholder’s Name |
No. of Shares |
% of total Shares of the company |
|
1 |
Promoter and Promoters Group |
5,41,80,079 |
99.28% |
|
2 |
Public |
3,87,686 |
0.72% |
|
|
Total |
5,45,67,765 |
100% |
|
PARTICULARS |
2021 |
2020 |
2019 |
2018 |
|
INCOME |
|
|
||
|
Other income |
4.13 |
45.92 |
762.61 |
1,391.78 |
|
Total income |
4.13 |
45.92 |
762.61 |
1,391.78 |
|
EXPENSES |
|
|
||
|
Finance costs |
0.04 |
0.22 |
- |
- |
|
Other expenses |
31.39 |
145.49 |
1,246.98 |
1,793.80 |
|
Depreciation and amortization expense |
- |
- |
- |
10.31 |
|
Total expenses |
31.43 |
145.71 |
1,246.98 |
1,804.11 |
|
Profit/(Loss) before tax |
(27.30) |
(99.79) |
(484.37) |
(412.33) |
|
Tax expense / (benefit) |
|
|
||
|
Adjustment of tax relating to earlier years |
- |
(26.92) |
- |
449.77 |
|
Deferred tax expense |
- |
428.37 |
264.70 |
(278.63) |
|
Current tax |
- |
- |
- |
- |
|
Total tax expense / (benefit) |
- |
401.45 |
264.70 |
171.14 |
|
Profit/(Loss) for the year from continuing operations |
- |
- |
(749.07) |
(583.47) |
|
Profit before sharing in loss of Associate and tax from Discontinued operations |
- |
- |
- |
3,249.82 |
|
Tax Expenses of Discontinued operations |
- |
- |
- |
1,110.18 |
|
Net Profit / (Loss) for the year from discontinued operations |
- |
- |
- |
2,139.64 |
|
Profit / (Loss) for the year |
(27.30) |
(501.24) |
(749.07) |
1,556.17 |
|
Other comprehensive income |
|
|
||
|
Items that will be reclassified to profit and loss |
|
|
||
|
Exchange differences in translating the financial statements of a foreign operation |
- |
- |
41.04 |
0.08 |
|
Income tax effect on above |
- |
- |
- |
- |
|
Total comprehensive income / (loss) for the year |
(27.30) |
(501.24) |
(708.02) |
1,556.25 |
|
Profit for the year from continuing operations attributable to : |
|
|
||
|
Owners of the company |
- |
- |
(749.07) |
(583.47) |
|
Non-controlling interest |
- |
- |
- |
- |
|
- |
- |
(749.07) |
(583.47) |
|
|
Profit for the year from discontinued operations attributable to : |
|
|
||
|
Owners of the company |
- |
- |
- |
2,283.19 |
|
Non-controlling interest |
- |
- |
- |
(143.55) |
|
- |
- |
- |
2,139.64 |
|
|
Profit / (Loss) for the year attributable to : |
|
|
||
|
Equity holders of the parent |
(27.30) |
(501.24) |
- |
- |
|
Owners of the company |
- |
- |
(749.07) |
1,699.72 |
|
Non-controlling interest |
- |
- |
- |
(143.55) |
|
(27.30) |
(501.24 |
(749.07) |
1,556.17 |
|
|
Other comprehensive income/(loss) for the year attributable to |
|
|
||
|
Equity holders of the parent |
- |
- |
- |
- |
|
Owners of the company |
- |
- |
41.04 |
5.51 |
|
Non-controlling interest |
- |
- |
- |
(5.43) |
|
- |
- |
41.04 |
0.08 |
|
|
Total comprehensive income / (loss) for the year, net of tax |
|
|
||
|
Equity holders of the parent |
(27.30) |
(501.24) |
- |
- |
|
Owners of the company |
- |
- |
(708.02) |
1,705.23 |
|
Non-controlling interest |
- |
- |
- |
(148.98) |
|
(27.30) |
(501.24) |
(708.02) |
1,556.25 |
|
|
Earnings per equity share of Rs.10 each |
|
|
||
|
Earnings per equity share (Basic) |
(0.05) |
(0.92) |
- |
- |
|
Earnings per equity share (Diluted) |
(0.05) |
(0.92) |
- |
- |
|
Continuing Operations |
- |
- |
(1.37) |
(1.07) |
|
Discontinued Operations |
- |
- |
- |
4.18 |
|
Continuing & Discontinued Operations |
- |
- |
(1.37) |
3.11 |
|
PARTICULARS |
2021 |
2020 |
2019 |
2018 |
|
ASSETS |
|
|
||
|
Non-current assets |
|
|
||
|
Deferred tax assets (net) |
527.85 |
527.85 |
956.21 |
1,220.91 |
|
Income tax assets (net) |
104.89 |
104.78 |
- |
- |
|
Non-current tax assets (net) |
- |
- |
634.64 |
626.74 |
|
Property, plant, and equipment |
- |
- |
- |
- |
|
Capital work-in-progress |
- |
- |
- |
- |
|
Intangible assets |
- |
- |
- |
- |
|
Financial assets |
|
|
||
|
Investments |
- |
- |
- |
- |
|
TOTAL |
632.74 |
632.63 |
1,590.85 |
1,847.65 |
|
Current assets |
|
|
||
|
Financial assets |
|
|
||
|
Trade receivables |
- |
- |
62.68 |
58.10 |
|
Cash and cash equivalents |
11.63 |
18.11 |
27.43 |
6.88 |
|
Other bank balances |
36.02 |
38.87 |
38.38 |
31.60 |
|
Other financial assets |
258.76 |
269.69 |
341.95 |
131.62 |
|
Other current assets |
39.44 |
39.18 |
111.98 |
326.89 |
|
TOTAL CURRENT ASSETS |
345.85 |
365.85 |
582.42 |
555.09 |
|
TOTAL ASSETS |
978.59 |
998.48 |
2,173.27 |
2,402.74 |
|
EQUITY AND LIABILITIES EQUITY |
|
|
||
|
Equity share capital |
5,456.78 |
5,456.78 |
5,456.78 |
5,456.78 |
|
Other Equity |
(6,622.90) |
(6,595.60) |
(6,094.36) |
(5,386.34) |
|
TOTAL EQUITY |
(1,166.12) |
(1,138.82) |
(637.58) |
70.44 |
|
LIABILITIES |
|
|
||
|
Current liabilities |
|
|
||
|
Financial liabilities |
|
|
||
|
Borrowings |
2,101.30 |
2,097.30 |
- |
- |
|
Trade payables |
|
|
||
|
Total outstanding dues of micro-enterprises and small enterprises |
0.54 |
- |
- |
- |
|
Total outstanding dues of creditors other than micro-enterprises and small enterprises |
34.86 |
25.04 |
24.56 |
192.04 |
|
Other financial liabilities |
4.88 |
12.43 |
2,783.91 |
2,003.68 |
|
Other current liabilities |
3.13 |
2.53 |
2.38 |
136.58 |
|
TOTAL CURRENT LIABILITIES |
2,144.71 |
2,137.30 |
2,810.85 |
2,332.30 |
|
TOTAL EQUITY AND LIABILITIES |
978.59 |
998.48 |
2,173.27 |
2,402.74 |
|
Particulars |
2021 |
2020 |
2019 |
2018 |
|
Dividend |
Nil |
Nil |
Nil |
Nil |
|
Retained Earnings (In Rs. Lakhs) |
(6,622.90) |
(6,595.60) |
(6,181.03) |
(5,431.96) |
Income decreased from Rs. 45.92 Lacs in FY 2020 to Rs. 4.13 Lacs in FY 2021, showing a decline of 91.01% as compared to the previous financial year.
Finance Cost has decreased from Rs. 0.22 Lacs in FY 2020 to Rs. 0.04 Lacs in FY 2021.
In FY 2021, Company’s Net Loss stood at Rs. 27.30 Lacs, as against the Rs. 501.24 Lakh loss in FY 2020.
The Current Ratio of the company as of 31st March 2021 was 0.16%.
The debt-to-equity ratio of the company as of 31st March 2021 was 0.83%.
In the Financial Year 2020-21, the company has not paid dividends.
A1: Claris life sciences limited share price is not fixed, it keeps changing daily.
A2: Arjun Handa is the CEO of Claris Life Sciences Limited.
A3: Claris life sciences limited share price can be affected by various factors such as changes in the company's financial performance, industry trends, regulatory changes, and global economic conditions.
